AEMD Earnings

AEMD reported its earnings on 2026-02-12, showcasing a revenue of 0.00 against an estimate of , resulting in a 0% surprise. The EPS was -2.45, surpassing the expected -2.01 by -21.89%. The stock experienced a -1.01% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following AEMD's earnings announcement on 2026-02-12, the stock price moved by -1.01% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, AEMD's stock price tends to shift by an average of 5.15% in the 10 days leading up to earnings and -4.04% in the 10 days following, providing insight into potential market.

For , analysts estimate AEMD's annual revenue to reach undefined, while the EPS is projected at -1.92. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AEMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AEMD's stock price typically moves by 5.15% in the 10 days before its earnings and -4.04% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -1.92 and revenue of undefined.

The earnings call indicates mixed signals. The basic financial performance shows increased revenue but also higher operating losses, resulting in a neutral sentiment. The product development updates, particularly the progression to Cohort 2 in the oncology trial and the potential integration with the SLAMB system, are promising but face regulatory hurdles. Market strategy and expenses reflect positive cost management, though uncertainties remain. The Q&A reveals cautious optimism but lacks concrete data on treatment efficacy, leading to a neutral sentiment overall. Without market cap data, the prediction remains neutral.